Bluebird Bio Secures Historic Medicaid Agreement for Sickle Cell Treatment
Monday, 11 March 2024, 12:45
Bluebird Bio Stock Surges on Landmark Medicaid Deal for Sickle Cell Therapy
Bluebird Bio's stock is up in premarket trading as they announce their first Medicaid outcomes-based agreement for sickle cell gene therapy, Lyfgenia.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.